Human Immunodeficiency Virus Type 1 Protease Inhibitors Block Toll-Like Receptor 2 (TLR2)- and TLR4-Induced NF-κB Activation

Ozlem Equils,1* Alan Shapiro,2† Zeynep Madak,1‡ Chunren Liu,1 and Daning Lu1

Ahmanson Department of Pediatrics, Division of Pediatric Infectious Diseases, Steven Spielberg Pediatric Research Center, Cedars-Sinai Medical Center, and David Geffen School of Medicine at UCLA,1 and Division of Pediatric Infectious Diseases, Mattel Children’s Hospital at UCLA, and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA,2 Los Angeles, California

Received 23 March 2004/Returned for modification 25 May 2004/Accepted 24 June 2004

Coinfections with opportunistic and pathogenic bacteria induce human immunodeficiency virus (HIV) replication through microbial antigen activation of NF-κB. Here, we assessed whether HIV type 1 protease inhibitors (PI) block microbial antigen activation of NF-κB. Human microvessel endothelial cells were transiently transfected with either endothelial cell-leukocyte adhesion molecule NF-κB luciferase or interleukin 6 (IL-6) promoter luciferase constructs by using FuGENE 6, and they were treated with PI (nelfinavir, ritonavir, or saquinavir) prior to stimulation with the Toll-like receptor 4 (TLR4) and TLR2 ligands, with lipopolysaccharide (LPS), soluble Mycobacterium tuberculosis factor, or Staphylococcus epidermidis phenol-soluble modulin, respectively, or with tumor necrosis factor alpha (TNF-α). Luciferase activity was measured by using a Promega luciferase kit. TNF-α release from the supernatant was measured by enzyme-linked immunosorbent assay. Cell death was assessed by lactate dehydrogenase assay. We observed that PI pretreatment blocked the TLR2- and TLR4- as well as the TNF-α-mediated NF-κB activation, in a dose-dependent manner. PI pretreatment also blocked the LPS-induced IL-6 promoter transactivation and TNF-α secretion. These data suggest that PI block HIV replication not only by inhibiting the HIV protease but also by blocking the TLR- and TNF-α-mediated NF-κB activation and proinflammatory cytokine production. These findings may help explain the immunomodulatory effects of PI, and they suggest an advantage for PI-containing drug regimens in the treatment of HIV-infected patients who are coinfected with opportunistic and pathogenic bacteria.

Human immunodeficiency virus (HIV) infection is characterized by persistent viral replication and progressive immune dysfunction. In HIV-infected patients, declining immunity leads to infections by a diverse range of microorganisms which induce HIV replication and lead to disease worsening (50, 57). The development of an opportunistic infection, such as Pneumocystis jiroveci pneumonia, cytomegalovirus infection, Mycobacterium avium complex disease, candida esophagitis, toxoplasmosis, or cryptosporidiosis, has been shown to be significantly associated with death in HIV-infected patients, independent of CD4 cell counts (5). In that study, the average monthly loss of CD4 cells in patients with opportunistic diseases was nearly double that of patients without opportunistic illness during a follow-up interval, which suggests that there is an increased HIV load during opportunistic infections (5). Therefore, it is extremely important to control HIV replication during concurrent microbial infections.

The activation of HIV type 1 (HIV-1) gene expression by many extracellular stimuli, including microbial antigens, is critically dependent upon the activation of NF-κB, which is known to bind to κB sites within the HIV-1 long terminal repeat (LTR) enhancer region (15, 19, 54, 55). Equils et al. have recently shown that lipopolysaccharide (LPS) induces HIV LTR transactivation through an innate immune system receptor, Toll-like receptor 4 (TLR4) (13), and that the stimulation of TLR2 with soluble Mycobacterium tuberculosis factor (STF) and Staphylococcus epidermidis phenol-soluble modulin (PSM) and TLR9 with bacterial CpG DNA activates HIV replication (14).

In addition, proinflammatory cytokines released during opportunistic infections (e.g., tumor necrosis factor alpha [TNF-α] and interleukin 6 [IL-6]) can activate NF-κB and induce HIV-1 replication in an autocrine and paracrine fashion (12, 23, 43, 47). NF-κB has also been shown to mediate the mitogen and viral infection activation of HIV replication (32, 39, 52). These data suggest that NF-κB plays a key role in HIV replication and HIV disease progression.

NF-κB is normally found in the inactive form in the cytoplasm, bound to IκBα (17). TLR stimulation initiates a signaling cascade that leads to IκBα degradation by 26S proteasome, which is an elongated structure consisting of a central 20S complex capped at either one end or both ends by 19S complexes (reviewed in references 26, 41, and 62). The 19S caps recognize ubiquitinated proteins and convert them into a form competent for degradation by the 20S complex (62). Active
NF-κB then moves into the nucleus and promotes gene transcription.

Protease inhibitors (PI) are a group of antiretroviral medications that block the HIV-1 aspartyl protease (8); however, indinavir, ritonavir, and saquinavir have also been shown to inhibit the 20S proteasome (2, 44, 46). In addition, nucleoside analogues, zidovudine, and lamivudine have been shown to inhibit the trypsin- and chymotrypsin-like activity of 20S proteasome (46).

Here, we examined the effect of PI (nelfinavir, ritonavir, saquinavir, and indinavir) on bacterial antigen and TNF-α activation of NF-κB and showed that pretreatment with PI blocked TNF-α, LPS-, and TLR4-induced NF-κB and IL-6 promoter transactivation. Nelfinavir blocked the TLR2-mediated NF-κB activation; however, it did not block the chymotrypsin-like activity of 20S proteasome. These results suggest that HIV protease inhibitors block microbial antigen-induced endothelial cell activation.

MATERIALS AND METHODS

Cells and reagents. The human dermal microvessel endothelial cells (HMEC) were a gift of F. J. Candal, Centers for Disease Control, Atlanta, Ga. (1). HMEC were cultured in MCDB 131 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 μg of penicillin/ml, and 100 μg of streptomycin/ml. The cells were routinely used between passages 10 and 14 as described earlier (13). PSM was prepared by phenol extraction of supernatants of stationary S. epidermidis (36), and was kindly obtained from Seymour Klebanoff (University of Washington, Seattle). STF was obtained from Terry K. Means and Matthew J. Fenton (Boston University, Boston, Mass.). All reagents were verified to be LPS free by the Limulus amebocyte lysate assay (Pyrotell, Association of Cape Cod, Mass.; <0.03 endotoxin units/ml). Highly purified, phenol-water-extracted, and protein-free (<0.0008% protein) Escherichia coli LPS, which was prepared by the method described by McIntire et al. (35), was obtained from S. N. Vogel (University of Maryland, College Park). Nelfinavir was obtained from Agouron Pharmaceuticals (San Diego, Calif.). Ritonavir, saquinavir, and indinavir were kindly obtained from Eric Daar (Harbor-UCLA Medical Center, Los Angeles).

TNF-α analysis. After 5 h of LPS stimulation, supernatants were analyzed for TNF-α production by using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, Minn.) according to the manufacturer’s instructions. All data for TNF-α are the averages ± standard deviations (SD) of results with triplicate samples. Each experiment was repeated at least twice.

Expression vectors. Wild-type human TLR2 was a gift from Ruslan Medzhitov (Yale University, New Haven, Conn.). The reporter plasmids pCMV-β-galactosidase (0.5 μg), endothelial cell-leukocyte adherence molecule (ELAM) NF-κB luciferase (0.5 μg), and IL-6 luciferase (0.5 μg) were used as previously described (16).

Transfection of HMEC. HMEC were plated at a concentration of 50,000 cells/well in 24-well plates and cultured overnight. Cells were cotransfected the next day with FuGENE 6 transfection reagent (Boehringer Mannheim, Indianapolis, Ind.) following the manufacturer’s instructions (16). The pCMV-β-galactosidase (0.1 μg) and either IL-6 promoter luciferase (0.5 μg) or ELAM NF-κB luciferase (0.5 μg) expression vectors were transfected into HMEC with or without human TLR2 cDNA (0.3 μg) (16). Cells were then stimulated for 6 h with various concentrations of LPS, STF, or PSM and lysed, and luciferase activity was measured with a luciferase assay kit (Promega, Madison, Wis.) and a luminometer. β-Galactosidase activity was determined by a colorimetric method as described previously (16).

RESULTS

PI block the LPS-induced NF-κB activation in a dose-dependent manner. PI have been shown to have immunomodulatory effects (7, 27, 29, 31, 56). We hypothesized that the immunomodulatory effects of HIV-1 PI may be due to PI inhibition of TLR-induced IκBα degradation and NF-κB activation. In order to test this hypothesis, we treated HMEC with various concentrations of PI, subjected them to LPS stimulation, and measured the luciferase activity.

Pretreatment with nelfinavir, ritonavir, and saquinavir inhibited the LPS-induced NF-κB activation (Fig. 1A). We then performed experiments using nelfinavir as a representative PI and observed that 1-h nelfinavir pretreatment blocked the LPS-induced NF-κB activation in a dose-dependent manner (Fig. 1B). Nelfinavir pretreatment of HMEC for various periods of time (30 to 120 min) had similar effects on LPS-induced NF-κB transactivation (data not shown). We assessed PI-induced cell death by measuring the supernatant lactate dehydrogenase release with a colorimetric lactate dehydrogenase assay (Roche Diagnostics). The concentrations of nelfinavir used in the experiments did not induce cell death (data not shown). These results suggest that PI block LPS-induced NF-κB activation.
Nelfinavir pretreatment blocks the TLR2-mediated NF-κB activation. In addition to TLR4, TLR2 has been shown to play a key role in the microbial antigen activation of NF-κB (64). We examined the effects of nelfinavir pretreatment of HMEC on NF-κB activation induced by TLR2 ligands PSM (21) and STF (4).

As with experiments with LPS, 1-h pretreatment of HMEC with nelfinavir suppressed the PSM- and STF-induced NF-κB activation (Fig. 2).

PI pretreatment of HMEC blocks the LPS-induced IL-6 promoter transactivation and TNF-α release. IL-6 is a proinflammatory cytokine produced by immune cells upon microbial antigen stimulation (18, 24, 32, 63), and IL-6 has been known to induce HIV replication (6, 28, 34). We assessed the effect of PI on LPS-induced IL-6 expression in HMEC transiently transfected with IL-6 promoter luciferase construct by treatment with PI (nelfinavir, saquinavir, indinavir, or ritonavir) 1 h prior to LPS stimulation and measurement of the luciferase activity. We observed that PI pretreatment down-regulated the LPS-induced IL-6 promoter activation approximately fourfold (Fig. 3).

In addition to IL-6 promoter transactivation, we assessed whether PI pretreatment of HMEC modulated the LPS-induced TNF-α release. HMEC were treated with PI (nelfinavir, saquinavir, ritonavir, or indinavir) 1 h prior to LPS stimulation, and TNF-α release was measured by ELISA. We observed that pretreatment with ritonavir, saquinavir, and indinavir blocked the LPS-induced TNF-α release; however, nelfinavir, at doses that were observed to inhibit LPS-induced NF-κB and IL-6 promoter activation, did not block TNF-α release (Fig. 4).
These results suggest that PI may inhibit LPS-induced proinflammatory cytokine production with different potencies.

**PI pretreatment of HMEC blocks TNF-α-induced NF-κB activation.** Infection with opportunistic and pathogenic bacteria leads to immune activation and proinflammatory cytokine release. TNF-α has been shown to be one of the key proinflammatory cytokines that induce NF-κB activation (51) and HIV LTR transactivation (12, 43). We assessed whether PI pretreatment of HMEC blocks TNF-α-induced NF-κB activation. One-hour PI (nelfinavir, ritonavir, saquinavir, or indinavir) pretreatment of HMEC down-regulated TNF-α (100 ng/ml) and induced NF-κB activation in a dose-dependent manner (Fig. 5). These results suggest that PI may also block TNF-α-induced NF-κB activation and HIV LTR transactivation during opportunistic infections.

**DISCUSSION**

Here, we show that HIV protease inhibitors block the TLR4- and TLR2-mediated microbial antigen activation of NF-κB by using microvessel endothelial cells. Vascular endothelial cells play a major role in the innate immune activation during infections and sepsis, and these cell lines are very well defined for their Toll-like receptor expression and microbial antigen response and signaling and have been used successfully to examine the role of TLR4 in LPS-induced HIV LTR transactivation (13, 14, 16).

The HIV protease plays an essential role in HIV replication, performing the posttranslational processing of the Gag and Gag-Pol proteins into the functional core proteins and viral enzymes (9). Inhibition of this enzyme leads to the production of...
of immature, noninfectious viral progeny, blocking further rounds of infection.

There is considerable indirect evidence that antiretroviral medications have immunologic effects that are independent of their effects on HIV replication. Treatment of two HIV-1-exposed patients with an antiretroviral regimen containing zidovudine, lamivudine, and indinavir has been reported to inhibit phorbol ester-induced cytokine release from their peripheral blood mononuclear cells (59). Patients who are treated with regimens that include PI appear to experience marked increases in CD4⁺-T-cell counts, and a large proportion of these patients experience discordant results with increased CD4⁺-T-cell counts despite the failure to suppress HIV viremia significantly (7, 10, 27, 29, 31, 56). These data suggest a possible action of antiretrovirals, including HIV protease inhibitors, on nonviral targets participating in the mechanisms of CD4 T-cell depletion. Here, we show that PI blocks the TLR2-, TLR4-, and TNF-α-induced NF-κB block the LPS-induced HIV LTR transactivation (13).

Our data suggest that part of the PI effect to block HIV replication may indirectly regulate HIV-1-induced CD4⁺-T-cell apoptosis, which may help explain the increase in CD4⁺-T-cell counts despite only moderate reductions in plasma HIV RNA levels.

Mitogens, cytokines, and environmental stresses activate HIV replication via NF-κB (15, 30, 40, 58, 61). It was previously shown that the deletion of NF-κB binding sites from HIV LTR and the pretreatment of cells with chemical inhibitors of NF-κB block the LPS-induced HIV LTR transactivation (13). Our data suggest that part of the PI effect to block HIV replication may be mediated through the inhibition of NF-κB. This observation may be especially relevant in HIV-infected patients who are coinfected with opportunistic and pathogenic bacteria.

NF-κB exists in dimers composed of various combinations of members of the NF-κB/Rel family (38, 53). In addition to their role in IκBα degradation, 26S proteasomes also mediate the proteolytic processing of the NF-κB precursor proteins p105 and p100 to yield p50 and p52, respectively (45, 42). The increased processing of p100 and p100 occurs in response to NF-κB-activating stimuli (3, 11, 37). Another potential mechanism by which HIV PI block microbial antigen activation of NF-κB may be the down-regulation of NF-κB precursor processing. We assessed whether nelfinaiv blocked the chromotrypsin-like activity of purified 20S proteasome by using a 20S proteasome assay kit (Biomol, Plymouth Meeting, Pa.). Briefly, an erythrocyte 20S proteasome preparation that was preactivated by SDS was added to succinyl-LLVY-7-amido-4-methylcoumarin fluorogenic peptide substrate with or without nelfinaiv. The proteasome inhibitor lactacystin was included as the positive control. We observed that in contrast to what has been reported for indinavir, ritonavir, and saquinavir (2, 44, 46), nelfinaiv did not inhibit 20S proteasome (data not shown).

Recently, Qureshi et al. have shown that LPS forms a complex with 20S proteasome in murine-macrophage membrane (48). Alternatively, PI may block LPS-20S proteasome complex formation in the cell membrane, which may help explain the inhibition of microbial antigen activation of NF-κB. Although we did not examine the ability of PI to inhibit TLR-ligand binding on the cell surface, our data suggest that PI pretreatment also blocks the TNF-α-induced NF-κB activation.

The PI we tested had different potencies for blocking the LPS- and TNF-α-induced NF-κB activation. This finding may be explained by the fact that PI utilize different mechanisms to inhibit the HIV protease. Saquinavir (49) and ritonavir (22) function as substrates for the substrate within the active site of the HIV protease dimer, whereas indinavir acts as a transition state analog (60) and nelfinaiv functions as nonpeptidomimetic protease inhibitor (25).

Overall, our results suggest that HIV protease inhibitors block microbial antigen- and TNF-α-induced NF-κB activation, which may potentially explain the immunomodulatory effect of PI.

ACKNOWLEDGMENTS

This work was supported by an Agouron Pharmaceuticals award to Ozlem Equils. The study on which this article is based was conducted while Alan Shapiro was a fellow in the Division of Pediatric Infectious Diseases at Mattel Children’s Hospital at UCLA and before he joined the staff of the Food and Drug Administration. The views expressed are those of the authors. No official support or endorsement by the Food and Drug Administration is provided or should be inferred.

We thank Paul Krogstad, David Geffen School of Medicine at UCLA, Los Angeles, Calif., for his critical review of the manuscript.

REFERENCES


